Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
DT Le, E Lutz, JN Uram, EA Sugar… - Journal of …, 2013 - journals.lww.com
Preclinical reports support the concept of synergy between cancer vaccines and immune
checkpoint blockade in nonimmunogenic tumors. In particular, cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) antibodies have been successfully combined with GM-CSF
cell-based vaccines (GVAX). Ipilimumab (anti-CTLA-4) has been tested as a single agent in
patients with pancreatic ductal adenocarcinoma (PDA) resulting in a delayed response at a
dose of 3 mg/kg. Our study evaluated ipilimumab 10 mg/kg (arm 1) and ipilimumab 10 …
checkpoint blockade in nonimmunogenic tumors. In particular, cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) antibodies have been successfully combined with GM-CSF
cell-based vaccines (GVAX). Ipilimumab (anti-CTLA-4) has been tested as a single agent in
patients with pancreatic ductal adenocarcinoma (PDA) resulting in a delayed response at a
dose of 3 mg/kg. Our study evaluated ipilimumab 10 mg/kg (arm 1) and ipilimumab 10 …